Stock Track | MICOT PHARMA-B Soars 89.56% in Early Trading on IPO Debut Amid Heavy Oversubscription and Promising Pipeline

Stock Track

06/24

MICOT PHARMA-B (02335) surged 89.56% in early trading as it made its debut on the Hong Kong Stock Exchange.

The dramatic rise was fueled by extraordinary investor demand, with the Hong Kong public offering oversubscribed 1,181.46 times. The company raised net proceeds of approximately HK$989 million to HK$1.067 billion from the issuance of 58.05 million shares at an offer price of HK$18.20 per share.

Investor enthusiasm is also driven by the company's clinical-stage pipeline. Its lead product, MT1013, is a dual-target receptor agonist peptide currently in Phase III trials for the treatment of secondary hyperparathyroidism in chronic kidney disease patients, with commercialization targeted for early 2028.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1111227454"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1111227454\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1111227454?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 09:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111227454","market":"hk","top_or_hot":-1,"title":"Stock Track | MICOT PHARMA-B Soars 89.56% in Early Trading on IPO Debut Amid Heavy Oversubscription and Promising Pipeline","media":"Stock Track","content":"<p>MICOT PHARMA-B (02335) surged 89.56% in early trading as it made its debut on the Hong Kong Stock Exchange.</p><p>The dramatic rise was fueled by extraordinary investor demand, with the Hong Kong public offering oversubscribed 1,181.46 times. The company raised net proceeds of approximately HK$989 million to HK$1.067 billion from the issuance of 58.05 million shares at an offer price of HK$18.20 per share.</p><p>Investor enthusiasm is also driven by the company's clinical-stage pipeline. Its lead product, MT1013, is a dual-target receptor agonist peptide currently in Phase III trials for the treatment of secondary hyperparathyroidism in chronic kidney disease patients, with commercialization targeted for early 2028.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | MICOT PHARMA-B Soars 89.56% in Early Trading on IPO Debut Amid Heavy Oversubscription and Promising Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | MICOT PHARMA-B Soars 89.56% in Early Trading on IPO Debut Amid Heavy Oversubscription and Promising Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-24 09:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MICOT PHARMA-B (02335) surged 89.56% in early trading as it made its debut on the Hong Kong Stock Exchange.</p><p>The dramatic rise was fueled by extraordinary investor demand, with the Hong Kong public offering oversubscribed 1,181.46 times. The company raised net proceeds of approximately HK$989 million to HK$1.067 billion from the issuance of 58.05 million shares at an offer price of HK$18.20 per share.</p><p>Investor enthusiasm is also driven by the company's clinical-stage pipeline. Its lead product, MT1013, is a dual-target receptor agonist peptide currently in Phase III trials for the treatment of secondary hyperparathyroidism in chronic kidney disease patients, with commercialization targeted for early 2028.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02335","symbol_name":"麦科医药-B","start_time":0,"source_url":"","article_id":"1111227454","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111227454","pubTimestamp":1782264920,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"MICOT PHARMA-B (02335) surged 89.56% in early trading as it made its debut on the Hong Kong Stock Exchange.The dramatic rise was fueled by extraordinary investor demand, with the Hong Kong public...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02335":"麦科医药-B"},"translate_title":"股票追踪|Micot Pharma-B IPO首秀早盘飙升89.56%，超额认购严重，管线前景看好","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02335":1},"content_text":"MICOT PHARMA-B (02335) surged 89.56% in early trading as it made its debut on the Hong Kong Stock Exchange.The dramatic rise was fueled by extraordinary investor demand, with the Hong Kong public offering oversubscribed 1,181.46 times. The company raised net proceeds of approximately HK$989 million to HK$1.067 billion from the issuance of 58.05 million shares at an offer price of HK$18.20 per share.Investor enthusiasm is also driven by the company's clinical-stage pipeline. Its lead product, MT1013, is a dual-target receptor agonist peptide currently in Phase III trials for the treatment of secondary hyperparathyroidism in chronic kidney disease patients, with commercialization targeted for early 2028.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}